Showing results (91-100 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|November 7, 2025
Functional cure of HIV-1 infection in an exceptional elite controller: a case reportJosé M Benito, Juan C Lopez-Bernaldo, Katie Fisher, et al.
The Lancet. HIV|November 1, 2025
Artificial intelligence in HIV research, policy, and clinical careSean D Young
The Lancet. HIV|December 6, 2025
Uptake of dapivirine vaginal ring and oral pre-exposure prophylaxis among women accessing HIV prevention services in South Africa: a cohort studyCatherine Elizabeth Martin, Hlologelo Ramatsoma, Glory Chidumwa, et al.
The Lancet. HIV|August 14, 2025
Research gaps for children who are HIV-exposed but uninfected: outcomes of a research prioritisation workshopCatherine J Wedderburn, Ceri Evans, Elaine J Abrams, et al.
The Lancet. HIV|October 11, 2025
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trialAdrie Bekker, Nicolas Salvadori, Helena Rabie, et al.
The Lancet. HIV|December 5, 2014
HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort studyJaimie P Meyer, Javier Cepeda, Sandra A Springer, et al.
The Lancet. HIV|November 29, 2015
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation studyJulian H Elliott, James H McMahon, Christina C Chang, et al.
The Lancet. HIV|February 6, 2016
Effect of a clinical decision support system on early action on immunological treatment failure in patients with HIV in Kenya: a cluster randomised controlled trialTom Oluoch, Abraham Katana, Daniel Kwaro, et al.
The Lancet. HIV|August 13, 2017
Household survey of HIV incidence in Rwanda: a national observational cohort studySabin Nsanzimana, Eric Remera, Steve Kanters, et al.
The Lancet. HIV|July 22, 2017
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b studyCatherine Orrell, Debbie P Hagins, Elena Belonosova, et al.
Pageof 79